Cefazolin versus flucloxacillin in bloodstream infections caused by methicillin-susceptible Staphylococcus aureus (MSSA): a quasi-randomized, prospective, observational study (CASABI)
Final Report Abstract
Several meta-analyses of predominantly retrospective studies suggest a significant better tolerability of Cefazolin versus antistaphylococcal penicillins in the therapy of Methicillinsusceptible Staphylococcus aureus (MSSA)-blood stream infections without compromise regarding its clinical effectiveness. However antistaphylococcal penicillins constitute the standard of care in most places as evidence from randomized-controlled trials directly comparing both regimens is still absent. This project was originally planned as preparation of such a trial to help clarify this debate. We prospectively included a total of 71 patients with MSSA-blood stream infections at two university hospitals who received either Cefazolin or Flucloxacillin (as representative agent for antistaphylococcal penicillins). Adverse effects and premature discontinuation of therapy were documented as well as data on infection characteristics and clinical and microbiological effectiveness.
